What is the therapeutic effect of using venetoclax/venetoclax combined with azacitidine?

Venetoclax/The combination therapy of Venetoclax and Azacitidine has attracted much attention in the treatment of acute myeloid leukemia (AML). These two drugs have their own characteristics and work together on cancer cells through different mechanisms in order to achieve better therapeutic effects.

Veneclase, as a selective small moleculeBCL2 inhibitor, its core mechanism is to induce apoptosis of malignant cells by inhibiting the function of BCL2 protein, thus playing a key role in the treatment of AML. In contrast, azacitidine is a nucleoside metabolism inhibitor whose main function is to interfere with the DNA synthesis and cell proliferation of tumor cells. When these two drugs are used together, they can produce a significant synergistic effect, thereby improving the overall therapeutic effect.

After verification in multiple clinical trials, the performance of the combination therapy of venetoclax and azacitidine in AML patients is indeed exciting. Compared with traditional monotherapy, this combination therapy can significantly extend the overall survival of patients and effectively reduce the risk of death. What is more worth mentioning is that the complete remission rate of combination therapy is higher, and the duration of complete remission is also longer. This undoubtedly means that with this treatment option, more patients can expect to achieve long-term disease control and significantly improve their quality of life.

From a safety perspective, this combination therapy also shows its advantages. Although both venetoclax and azacitidine have certain side effects, there is no significant increase in the incidence of adverse reactions when they are used together. The vast majority of patients tolerate this treatment regimen well and maintain a relatively high quality of life during treatment.

In summary, venetoclax combined with azacitidine is an effective and relatively safe treatment option for AML. It improves treatment effects through synergy, bringing patients better survival prognosis and quality of life. However, the selection and implementation of treatment plans need to be carried out under the guidance of professional doctors to ensure that patients can obtain the best treatment results.